Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2017-07-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/13543776.2017.1297797PMID 28270021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I

  2017cited by this paper
• The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

  2016cited by this paper
• Comprehensive characterization of the Published Kinase Inhibitor Set

  2016influential reference
• Structural characterization of nonactive site, TrkA-selective kinase inhibitors

  2016cited by this paper
• Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

  2016cited by this paper
• Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101

  2016influential reference
• Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

  2016influential reference
• What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

  2016cited by this paper
• When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program

  2016cited by this paper
• Anti-nerve growth factor in pain management: current evidence

  2016cited by this paper
• The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

  2016influential reference
• Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

  2016cited by this paper
• Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

  2016influential reference
• Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

  2016cited by this paper
• NTRK3 kinase fusions in Spitz tumours

  2016cited by this paper
• Are we systematically under-dosing patients with fluorouracil?

  2015cited by this paper
• An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

  2015influential reference
• Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

  2015cited by this paper
• Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations.

  2015cited by this paper
• Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

  2015cited by this paper
• Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

  2015cited by this paper
• Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

  2015cited by this paper
• Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

  2015cited by this paper
• A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

  2015cited by this paper
• Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

  2015cited by this paper
• STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

  2015cited by this paper
• TRKing down an old oncogene in a new era of targeted therapy.

  2015influential reference
• (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

  2015cited by this paper
• Basket trials and the evolution of clinical trial design in an era of genomic medicine.

  2015cited by this paper
• Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double‐blind, placebo‐controlled exploratory study in osteoarthritis of the knee

  2014cited by this paper
• The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

  2014cited by this paper
• Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain.

  2014influential reference
• Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013

  2014cited by this paper
• Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.

  2014cited by this paper
• Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

  2013cited by this paper
• Activation of TrkB with TAM-163 Results in Opposite Effects on Body Weight in Rodents and Non-Human Primates

  2013cited by this paper
• Anti‐tumour efficacy on glioma models of PHA‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier

  2013cited by this paper
• Tropomyosin-related kinase inhibitors

  2013cited by this paper
• Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

  2013cited by this paper
• Nerve growth factor‐mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management

  2013cited by this paper
• Efficacy, safety, and tolerability of fulranumab, an anti‐nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

  2013cited by this paper
• Targeting Nerve Growth Factor in Pain

  2012cited by this paper
• The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

  2012cited by this paper
• Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

  2012cited by this paper
• Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors tropomyosin-related kinases

  2012cited by this paper
• Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

  2012influential reference
• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in treatment of patients with moderate-to-severe osteoarthritis pain

  2011cited by this paper
• Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

  2011cited by this paper
• Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma

  2010cited by this paper
• Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

  2010cited by this paper
• Tanezumab for the treatment of pain from osteoarthritis of the knee.

  2010cited by this paper
• Trk kinase inhibitors as new treatments for cancer and pain

  2009cited by this paper
• Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

  2009cited by this paper
• Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.

  2005cited by this paper
• Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB

  2004cited by this paper
• TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.

  2004cited by this paper
• Nerve growth factor receptors and signaling in breast cancer.

  2004cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• Anti-ngf antibodies and methods using same

  2003cited by this paper
• The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

  2003cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation

  2002cited by this paper
• ETV6-NTRK3--Trk-ing the primary event in human secretory breast cancer.

  2002cited by this paper
• Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.

  2001cited by this paper
• Trk receptor tyrosine kinases: a bridge between cancer and neural development.

  2001cited by this paper
• Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

  2001cited by this paper
• Neurotrophins: roles in neuronal development and function.

  2001cited by this paper
• Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.

  1999cited by this paper
• Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.

  1998cited by this paper
• N'-tetracarboxylic-3,4,9,10-dialkylperylen process for the preparation of N,

  1996cited by this paper
• Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

  1993cited by this paper
• Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF

  1991cited by this paper
• trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3.

  1991influential reference
• The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3.

  1991influential reference
• The trk proto-oncogene encodes a receptor for nerve growth factor.

  1991cited by this paper
• A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

  1986cited by this paper
• Oncogenes in solid human tumours

  1982cited by this paper
• Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia

  year unknowncited by this paper

• Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors

  2025cites this paper
• Recent advances in tropomyosin receptor kinase (TRK) inhibitors: a 2023–2024 patent landscape review

  2025cites this paper
• Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update

  2024cites this paper
• Discovery and Hit to Lead Optimization of Macrocyclic Peptides as Novel Tropomyosin Receptor Kinase A Antagonists.

  2024cites this paper
• Anticancer activity of new triazolopyrimidine linked coumarin and quinolone hybrids: synthesis, molecular modeling, TrkA, PI3K/AKT and EGFR inhibition

  2024cites this paper
• Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.

  2023cites this paper
• Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update

  2023cites this paper
• RECENT ADVANCES IN THE SYNTHESIS, REACTIVITY AND BIOLOGICAL PROPERTIES OF PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES : A REVIEW (2017-2022)

  2023cites this paper
• Potential Benefits of Dietary Plant Compounds on Normal and Tumor Brain Cells in Humans: In Silico and In Vitro Approaches

  2023influential citation
• Research Progress on Small Molecules Inhibitors Targeting TRK Kinases.

  2022cites this paper
• Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.

  2022cites this paper
• Adenocarcinomas of the Lung and Neurotrophin System: A Review

  2022cites this paper
• Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.

  2022cites this paper
• Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.

  2022cites this paper
• Abnormal TPM2 expression is involved in regulation of atherosclerosis progression via mediating RhoA signaling in vitro

  2021cites this paper
• Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs

  2021cites this paper
• In Pursuit of an Allosteric Human Tropomyosin Kinase A (hTrkA) Inhibitor for Chronic Pain.

  2021cites this paper
• Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments

  2021cites this paper
• Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.

  2021cites this paper
• Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.

  2021cites this paper
• Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.

  2020cites this paper
• Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019

  2020cites this paper
• Identification of Potential Hub Genes of Atherosclerosis Through Bioinformatic Analysis

  2020cites this paper
• Allosterische Kinaseinhibitoren – Erwartungen und Chancen

  2020cites this paper
• Interplay of BDNF and GDNF in the Mature Spinal Somatosensory System and Its Potential Therapeutic Relevance

  2020cites this paper
• Future directions in preclinical and translational cancer neuroscience research

  2020cites this paper
• Targeting tropomyosin receptor kinase for cancer therapy.

  2019cites this paper
• New Promise and Opportunities for Allosteric Kinase Inhibitors.

  2019cites this paper
• Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase

  2019cites this paper
• An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue.

  2019cites this paper
• Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.

  2019cites this paper
• TPM2 as a potential predictive biomarker for atherosclerosis

  2019cites this paper
• Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.

  2019cites this paper
• Identifying Plasma Derived Extracellular Vesicle (EV) Contained Biomarkers in the Development of Chronic Neuropathic Pain.

  2019cites this paper
• Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas

  2018cites this paper
• The study of TrkB pathway on vascular endothelial permeability by regulating the synthesis of VE-cadherin and inhibiting the degradation of VE-cadherin

  2018cites this paper
• Translocation-Related Sarcomas

  2018cites this paper
• Larotrectinib for the treatment of TRK fusion solid tumors

  2018cites this paper
• QSAR modelling: a therapeutic patent review 2010-present

  2018cites this paper
• Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.

  2018cites this paper
• From Cancer to Pain Target by Automated Selectivity Inversion of a Clinical Candidate.

  2018cites this paper
• GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models

  2018cites this paper
• Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

  2018cites this paper
• The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII

  2018cites this paper
• Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I

  2017cites this paper
• Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells

  2017cites this paper
• A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.

  2017cites this paper